Haisco(SZ:002653)2024-07-11 11:05Financial Performance - The estimated net profit attributable to shareholders for the first half of 2024 is projected to be between 150 million and 165 million CNY, representing a year-on-year increase of 99.80% to 119.78% compared to 75.08 million CNY in the same period last year [4]. - The expected net profit after deducting non-recurring gains and losses is estimated to be between 74 million and 85 million CNY, with a slight increase of 0.12% to 15.00% compared to 73.91 million CNY in the previous year [4]. - The company achieved a revenue growth of approximately 20% during the reporting period, driven by the rapid growth of products such as 环泊酚 [5]. Non-Recurring Items - The company received government subsidies of approximately 73 million CNY during the reporting period, which was not present in the same period last year, significantly impacting non-recurring gains and losses [5]. - The company terminated the licensing cooperation with Aquestive for the development of the drug 利鲁唑, resulting in an asset impairment provision of 53.45 million CNY [6]. - The equity method recognized a loss of approximately 43 million CNY from the investment in 海保人寿保险股份有限公司, which increased by about 24 million CNY compared to the same period last year [6]. Audit and Reporting - The financial data in this earnings forecast has not been audited by a registered accounting firm [5]. - The specific financial data will be detailed in the company's 2024 semi-annual report [7].